JPWO2020037150A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020037150A5 JPWO2020037150A5 JP2021507761A JP2021507761A JPWO2020037150A5 JP WO2020037150 A5 JPWO2020037150 A5 JP WO2020037150A5 JP 2021507761 A JP2021507761 A JP 2021507761A JP 2021507761 A JP2021507761 A JP 2021507761A JP WO2020037150 A5 JPWO2020037150 A5 JP WO2020037150A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- linker
- antigen
- seq
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 94
- 102000004196 processed proteins & peptides Human genes 0.000 claims 94
- 108090000765 processed proteins & peptides Proteins 0.000 claims 94
- 239000000427 antigen Substances 0.000 claims 33
- 102000036639 antigens Human genes 0.000 claims 33
- 108091007433 antigens Proteins 0.000 claims 33
- 235000018102 proteins Nutrition 0.000 claims 29
- 102000004169 proteins and genes Human genes 0.000 claims 29
- 108090000623 proteins and genes Proteins 0.000 claims 29
- 238000006467 substitution reaction Methods 0.000 claims 15
- 235000001014 amino acid Nutrition 0.000 claims 13
- 102000007238 Transferrin Receptors Human genes 0.000 claims 9
- 108010033576 Transferrin Receptors Proteins 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 7
- 230000004048 modification Effects 0.000 claims 7
- 238000012986 modification Methods 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 5
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 5
- 235000018417 cysteine Nutrition 0.000 claims 4
- IEMCJUJOHAEFFW-UHFFFAOYSA-M potassium 2-[(2-acetyloxybenzoyl)amino]ethanesulfonate Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NCCS(=O)(=O)[O-].[K+] IEMCJUJOHAEFFW-UHFFFAOYSA-M 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- 230000002378 acidificating effect Effects 0.000 claims 3
- 239000000539 dimer Substances 0.000 claims 3
- 239000012636 effector Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 150000001945 cysteines Chemical group 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 241000024188 Andala Species 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- -1 aromatic amino acid Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000005734 heterodimerization reaction Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862765095P | 2018-08-16 | 2018-08-16 | |
| US62/765,095 | 2018-08-16 | ||
| PCT/US2019/046705 WO2020037150A2 (en) | 2018-08-16 | 2019-08-15 | Engineered bispecific proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021533779A JP2021533779A (ja) | 2021-12-09 |
| JPWO2020037150A5 true JPWO2020037150A5 (enExample) | 2022-08-22 |
| JP7397063B2 JP7397063B2 (ja) | 2023-12-12 |
Family
ID=69525976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507761A Active JP7397063B2 (ja) | 2018-08-16 | 2019-08-15 | 操作された二重特異性タンパク質 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220017634A1 (enExample) |
| EP (1) | EP3850007A4 (enExample) |
| JP (1) | JP7397063B2 (enExample) |
| KR (1) | KR20210064199A (enExample) |
| CN (1) | CN112839955A (enExample) |
| AU (1) | AU2019320803A1 (enExample) |
| BR (1) | BR112021002730A2 (enExample) |
| CA (1) | CA3109763A1 (enExample) |
| EA (1) | EA202190542A1 (enExample) |
| IL (1) | IL280882A (enExample) |
| MA (1) | MA53616A (enExample) |
| MX (1) | MX2021001711A (enExample) |
| SG (1) | SG11202101273VA (enExample) |
| WO (1) | WO2020037150A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2932759T3 (es) | 2017-02-17 | 2023-01-25 | Denali Therapeutics Inc | Polipéptidos de unión al receptor de transferrina diseñados |
| MA50746A (fr) | 2017-10-02 | 2020-08-12 | Denali Therapeutics Inc | Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive |
| CN113614110B (zh) | 2019-02-20 | 2025-03-25 | 戴纳立制药公司 | 抗trem2抗体及其使用方法 |
| AU2020411480B2 (en) | 2019-12-23 | 2023-12-21 | Denali Therapeutics Inc. | Progranulin variants |
| AU2021208482B2 (en) | 2020-01-13 | 2025-12-11 | Denali Therapeutics Inc. | Anti-TREM2 antibodies and methods of use thereof |
| CR20230178A (es) | 2020-10-14 | 2023-07-26 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas |
| JP2024534824A (ja) * | 2021-08-25 | 2024-09-26 | デナリ セラピューティクス インコーポレイテッド | 操作された抗ｈｅｒ２二重特異性タンパク質 |
| KR20240116743A (ko) * | 2021-11-09 | 2024-07-30 | 한양대학교 산학협력단 | Fc 변이체를 포함하는 이종이합체 및 이의 제조방법 |
| US20250145729A1 (en) * | 2021-12-17 | 2025-05-08 | Denali Therapeutics Inc. | Polypeptide engineering, libraries, and engineered cd98 heavy chain and transferrin receptor binding polypeptides |
| US12011489B2 (en) * | 2022-03-30 | 2024-06-18 | Christopher Key | Compositions and methods for treating inflammatory disease |
| JP2025525792A (ja) | 2022-07-29 | 2025-08-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | トランスフェリン受容体１に対して再標的化されるウイルス粒子 |
| AU2023312978A1 (en) | 2022-07-29 | 2025-03-20 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:payload fusions and methods of use thereof |
| AU2023314808A1 (en) | 2022-07-29 | 2025-03-20 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
| CN118221803A (zh) * | 2022-12-19 | 2024-06-21 | 深圳科兴药业有限公司 | 异源二聚体Fc融合蛋白及其用途 |
| AR133384A1 (es) | 2023-07-28 | 2025-09-24 | Regeneron Pharma | Anti-tfr:esfingomielinasa ácida para el tratamiento de la deficiencia de esfingomielinasa ácida |
| AU2024317483A1 (en) | 2023-07-28 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005077981A2 (en) * | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
| US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| JP6226752B2 (ja) * | 2012-02-09 | 2017-11-08 | 中外製薬株式会社 | 抗体のＦｃ領域改変体 |
| SG11201509566RA (en) * | 2013-05-20 | 2015-12-30 | Genentech Inc | Anti-transferrin receptor antibodies and methods of use |
| CA2944402A1 (en) * | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| PE20221007A1 (es) * | 2015-06-24 | 2022-06-15 | Hoffmann La Roche | Anticuerpos anti-receptor de transferrina con afinidad disenada |
| EP3313890A1 (en) * | 2015-06-24 | 2018-05-02 | H. Hoffnabb-La Roche Ag | Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use |
| TWI769982B (zh) * | 2015-06-24 | 2022-07-11 | 日商Ｊｃｒ製藥股份有限公司 | 通過血腦障壁之抗人類運鐵蛋白受體抗體 |
| AU2016323440B2 (en) * | 2015-09-15 | 2023-07-13 | Amgen Inc. | Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof |
| US10457717B2 (en) * | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
| JP2020508054A (ja) * | 2017-02-17 | 2020-03-19 | デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 抗タウ抗体及びその使用方法 |
| ES2932759T3 (es) * | 2017-02-17 | 2023-01-25 | Denali Therapeutics Inc | Polipéptidos de unión al receptor de transferrina diseñados |
| WO2018237338A1 (en) * | 2017-06-23 | 2018-12-27 | Denali Therapeutics Inc. | Anti-alpha-synuclein antibodies and methods of use thereof |
| JP7403441B2 (ja) * | 2017-09-14 | 2023-12-22 | デナリ セラピューティクス インコーポレイテッド | 抗ｔｒｅｍ２抗体及びその使用方法 |
| MA50746A (fr) * | 2017-10-02 | 2020-08-12 | Denali Therapeutics Inc | Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive |
| WO2019094576A1 (en) * | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Bace-tau bispecific antibodies |
| WO2019094608A1 (en) * | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anti-bace1 antibodies and methods of use thereof |
| WO2019140050A1 (en) * | 2018-01-10 | 2019-07-18 | Denali Therapeutics Inc. | Transferrin receptor-binding polypeptides and uses thereof |
| US20210284702A1 (en) * | 2018-06-18 | 2021-09-16 | Denali Therapeutics Inc. | Fusion proteins comprising progranulin |
-
2019
- 2019-08-15 CN CN201980066244.0A patent/CN112839955A/zh active Pending
- 2019-08-15 EP EP19849330.6A patent/EP3850007A4/en not_active Withdrawn
- 2019-08-15 KR KR1020217007602A patent/KR20210064199A/ko not_active Withdrawn
- 2019-08-15 SG SG11202101273VA patent/SG11202101273VA/en unknown
- 2019-08-15 MA MA053616A patent/MA53616A/fr unknown
- 2019-08-15 EA EA202190542A patent/EA202190542A1/ru unknown
- 2019-08-15 CA CA3109763A patent/CA3109763A1/en active Pending
- 2019-08-15 BR BR112021002730-0A patent/BR112021002730A2/pt not_active IP Right Cessation
- 2019-08-15 MX MX2021001711A patent/MX2021001711A/es unknown
- 2019-08-15 WO PCT/US2019/046705 patent/WO2020037150A2/en not_active Ceased
- 2019-08-15 JP JP2021507761A patent/JP7397063B2/ja active Active
- 2019-08-15 AU AU2019320803A patent/AU2019320803A1/en not_active Abandoned
-
2021
- 2021-02-11 US US17/174,231 patent/US20220017634A1/en not_active Abandoned
- 2021-02-15 IL IL280882A patent/IL280882A/en unknown